Lymphoma Outcomes Hinge on Oncology, Not Viral Load In People With HIV

Oncologic factors, not HIV viral suppression status, determine how well people with HIV fare after a lymphoma diagnosis, according to a retrospective cohort study published in HIV Medicine.¹

Lymphoma Risk Persists in the ART Era

Lymphoma has remained one of the most common cancers in people with HIV since the earliest years of the epidemic, and that risk has persisted even as antiretroviral therapy (ART) transformed HIV from a fatal illness into a manageable chronic condition.

A 2024 protocol published in BMJ Open, outlining a planned systematic review to quantify that excess burden worldwide, noted that people with AIDS face roughly 400 times the risk of high-grade non-Hodgkin lymphoma (NHL) and about 15 times the risk of low-grade NHL compared with the general population.²

Because ART has sharply reduced AIDS-defining malignancies, clinicians have debated whether virologic control should factor into how aggressively to treat a lymphoma, or whether oncologic staging and histology alone should drive therapy. A multicenter retrospective study of Spain's CoRIS cohort set out to answer that question, comparing lymphoma outcomes between people with detectable viral load and those with sustained suppression at diagnosis.¹

A Retrospective Look at Spain's CoRIS Cohort

CoRIS is an open, prospective, multicenter cohort of adults with confirmed HIV infection, recruited at 48 centers in Spain since 2004. Among 18,573 people with HIV included in CoRIS, 291 (1.57%) were diagnosed with Hodgkin lymphoma (HL) or NHL between January 2004 and November 2022. Viral load data at the time of diagnosis were available for 245 of these individuals, who made up the study population.

Virologic suppression was defined as an HIV-1 RNA level below 100 copies per mL in all available measurements taken within the 6 months before diagnosis and the month after. Using that definition, 49 patients (20%) had suppressed viral load at diagnosis, while 196 (80%) had detectable virus. The researchers assessed lymphoma-specific mortality at 1 year and overall survival at 5 years using Kaplan-Meier estimates and multivariable Cox models adjusted for age, CD4 count, lymphoma type, and HIV duration.

Prognosis Tracked With Tumor Factors, Not Viral Load

People with detectable HIV viral load at lymphoma diagnosis presented with more aggressive disease than those with suppression. They had markedly lower CD4 counts (median, 180 cells/mm³ vs 371 cells/mm³; P < .001) and were more likely to have advanced Ann Arbor stage III or IV disease (82.0% vs 64.1%; P = .027). Despite that, they had a similar treatment response, with complete remission in 67.1% of the detectable-viral-load group compared with 76.2% of the suppressed group, and comparable relapse rates (16.3% vs 18.4%; P = .779).

Survival outcomes followed the same pattern. In multivariable analysis, viral suppression status at diagnosis was not independently associated with 5-year overall survival (HR, 0.85; 95% CI, 0.42-1.74) or with 1-year lymphoma-specific survival (HR, 1.03; 95% CI, 0.39-2.73). Conventional oncologic and immunologic factors did predict 5-year overall survival: each 10-year increase in age at diagnosis raised the risk of death by 28%, a CD4 count of 200 cells/mm³ or higher lowered 5-year mortality risk by 44%, and having HL rather than NHL was associated with a 70% lower 5-year mortality risk.

“These findings support that the management of Hodgkin and NHLs in PLWH should be primarily guided by standard oncohaematological criteria, with concomitant ART, regardless of HIV viral suppression status,” the researchers wrote.

Retrospective Design Carried Several Limitations

The authors acknowledged limitations tied to the retrospective design. Some lymphoma cases were excluded for missing viral load data, and histology could not be determined for 25 patients, though sensitivity analyses excluding these cases produced consistent results. Ann Arbor stage was documented for only a subset of patients, so it could not be included in the multivariable survival models, and the suppression definition incorporated some viral load measurements taken shortly after diagnosis, raising a small risk of misclassification.

The study also lacked a comparison group of people without HIV and could not evaluate immunologic or inflammatory biomarkers or coinfection with Epstein-Barr virus or human herpesvirus 8 that may contribute to lymphoma development even after viral suppression is achieved. Because CoRIS draws exclusively from Spanish treatment centers, the findings may not generalize to health systems with different HIV care patterns or patient populations.

Oncologic Criteria, Not ART Status, Should Guide Care

The results suggest that ART has changed what drives lymphoma's course in people with HIV, even though it has not eliminated the disease. Tumor biology, including stage, histology, and CD4-based immune recovery, appears to separate patients who respond well from those who do not, regardless of whether HIV replication itself is controlled.

For oncologists and HIV specialists coordinating care, the clinical implication is narrow but useful: a patient's viral suppression status should not, on its own, prompt a more conservative or more aggressive lymphoma treatment plan. Standard oncologic staging and regimens, delivered alongside continued ART, produced similar remission and survival regardless of suppression status in this cohort, supporting a treatment approach guided by the cancer rather than the virus.

References

1. Aldámiz-Echevarría T, Tejerina F, Fanciulli C, et al. Hodgkin and non-Hodgkin lymphomas in the post-antiretroviral therapy era according to HIV virological suppression. HIV Med. 2026;27(8):1312-1332. doi:10.1111/hiv.70257
2. Jacobson-Sive K. Study to quantify non-Hodgkin lymphoma risk in HIV. AJMC^®️. Published July 6, 2024. Accessed October 8, 2026. https://www.ajmc.com/view/study-to-quantify-non-hodgkin-lymphoma-risk-in-hiv